Newsletter Tool

Fact Sheet: OptiDose®️ Design Solution

Discover Catalent’s new OptiDose®️ Design Solution, a comprehensive drug design assessment consisting of a holistic review of the molecule, patient, and market consideration. Learn more.

Today's Rundown

Ironing out delivery wrinkles, Galderma posts phase 3 wins for liquid botulinum toxin A on route to FDA
Chasing Sage, PureTech’s oral depression drug clears early bioavailability test
Biologics delivery startup Elektrofi bags $40M for clinical push
Bacteria-triggered drug release system clears preclinical tests
The top 10 most profitable pharma companies in 2021
'The Top Line' podcast: ASCO data that wowed, rising stars blurring the line between traditional and tech-enabled drugs, plus this week’s headlines

Featured Story

Ironing out delivery wrinkles, Galderma posts phase 3 wins for liquid botulinum toxin A on route to FDA

By Nick Paul Taylor

Galderma has chalked up a pair of phase 3 wins for its liquid formulation botulinum toxin A, positioning it to submit the candidate for approval in the U.S. and other global markets. The formulation is designed to eliminate the need to reconstitute the aesthetic treatment from powder.

Webinar: Unraveling the Complexities in Nasal Vaccine Development, Manufacturing and Device Selection

Wednesday, June 29 | 11am ET / 4pm GMT / 5pm CET

In this webinar, experts will share insights into developing intranasal vaccine analytical tools and how to improve the speed and quality of critical batch release and characterization assays. Register Now.

Chasing Sage, PureTech’s oral depression drug clears early bioavailability test

By Nick Paul Taylor

PureTech Health has cleared an early hurdle in its pursuit of Sage Therapeutics, linking its oral prodrug of allopregnanolone to a nine-fold increase in the blood levels achieved by the unmodified molecule. Based on the data, the company is forging ahead with a view to starting a phase 1b/2a clinical trial next year.

Biologics delivery startup Elektrofi bags $40M for clinical push

By Nick Paul Taylor

Elektrofi has secured funding to support the advance of candidates based on its drug delivery technology into the clinic. Having landed deals with companies including Argenx and Takeda, the biologics delivery specialist has raised $40 million to establish a GMP manufacturing line and double its head count.

Bacteria-triggered drug release system clears preclinical tests

By Nick Paul Taylor

Researchers have developed a hydrogel that releases its payload when exposed to enzymes produced by certain bacteria, opening the door to a smart drug delivery system that could help minimize the risk of drug resistance.

The top 10 most profitable pharma companies in 2021

By Angus Liu,Eric Sagonowsky,Kevin Dunleavy,Fraiser Kansteiner,Zoey Becker

While revenue reflects how well a pharma company’s products and services are selling, profit represents another important measurement that provides investors a look at the health of the business and how efficiently it has been managed. Here, we rank the top 10 pharma companies by 2021 net income.

'The Top Line' podcast: ASCO data that wowed, rising stars blurring the line between traditional and tech-enabled drugs, plus this week’s headlines

By Teresa Carey

This week on "The Top Line," we discuss our special report on the rising stars in the digital health sector. We also talk about surprising data from this weekend’s ASCO meeting and the week's other big headlines. Plus, we're back in person at the biggest conferences!

Webinar: Mapping the Pathway to Designing Successful Treatment

Download this webinar to hear experts present evidence on how the right guidance at the right time can help you create more successful treatments for all stakeholders. Watch today.